Pharming Group announces third quarter 2026 revenues above market expectations

Pharming reported preliminary, unaudited Q3 2026 revenue of approximately US$117.6 million, up 21% year over year, while operating expenses were approximately US$74.6 million, in line with Q3 2025. The company narrowed its 2026 revenue guidance to US$380 million–US$390 million from US$375 million–US$395 million; full results and a business update are scheduled for October 27, 2026.

Analysis

The positive headline signal is weaker than the revenue growth rate implies: the guidance range was narrowed around the same midpoint, not raised. That suggests the market should focus on whether Q3 growth is repeatable and whether management can explain the unchanged full-year midpoint—not simply extrapolate one quarter. Flat operating expenses alongside higher revenue could indicate operating leverage, but preliminary, unaudited figures do not establish that the mix is recurring or that cash generation improved.

The key near-term catalyst is the October 27 full release. Inspect product-level revenue, geographic mix, gross margin, cash flow, receivables/inventory, and the bridge from Q3 performance to the full-year range. A favorable read-through would be diversified, recurring demand with stable margins; concentration, timing effects, or weaker-than-expected Q4 assumptions would undermine the growth narrative. Over 6–18 months, sustained expense discipline could support a better earnings-quality multiple, while dependence on a small number of rare-disease products leaves the thesis exposed to access, competition, and patient-demand volatility.

Contrarian point: investors may treat the 21% increase as an estimate-raising event, but the unchanged midpoint makes this primarily a quality-of-growth test. Without valuation, consensus, cash-flow, or product-mix data, there is no defensible basis for a price target or an aggressive directional position ahead of the release.

Key Decisions for Investors

• Do not chase PHAR solely on the preliminary revenue figure; treat the October 27 release as the decision point. Verify product/geographic mix, gross margin, cash flow, and the Q4 assumptions underlying the unchanged guidance midpoint.
• Conditional trade: consider a modest PHAR long only if the full release confirms broad-based recurring growth, stable or improving margins, and no deterioration in cash conversion. Reassess or exit if management attributes growth to timing/mix effects or narrows the outlook downward.
• For event exposure, consider a defined-risk call spread only if option liquidity and implied volatility are reasonable; otherwise stay flat through the binary catalyst. No valuation or options data were supplied to establish attractive entry levels.
• Falsification/watch items: a downward guidance revision, weaker-than-expected cash conversion, or evidence that Q3 growth is concentrated or non-recurring. A positive result would require confirmation that operating-expense discipline persists beyond this quarter.